WALTHAM, Mass.--(BUSINESS WIRE)--SHYFT Analytics, a Medidata company (NASDAQ: MDSO), today announced that it has significantly enhanced the real-world evidence (RWE) components of its solution platform. This expansion includes the appointment of key leadership positions that allow the company to cater to a broader range of life science organizations, including large biopharma companies, emerging biotechs, and contract research organizations (CROs).
The expanded RWE solutions team will serve as a dedicated resource and will focus solely on supporting the life science industry’s data analytics and evidence generation needs. SHYFT’s comprehensive RWE offering combines its groundbreaking QUANTUM RWE technology with decades of in-house data analytics expertise, advanced data science capabilities, and a full-suite of RWE consulting services that allow SHYFT to cater to life science organizations with varying levels of real-world experience. These services include, but are not limited to data source identification, analytics best practices consulting, and full outcomes study generation.
Leading the strategy behind this initiative will be Bruno Lempernesse and Aaron Galaznik, MD – two recent additions to SHYFT who add more than thirty years of experience in outcomes research and delivery of RWE products and services to market.
As vice president and general manager of the SHYFT RWE solutions team, Lempernesse will focus on executing and accelerating the evidence generation strategies of SHYFT’s biopharma and CRO partners. Prior to joining SHYFT, Lempernesse was the CEO of Inflexxion, an industry leader for clinical assessment and RWE related to substance use and drug abuse.
Galaznik, as head of research, will lead a team working hand-in-hand with customers and partners to execute and inform research strategy, and support the growing RWE needs of the industry. Prior, he served in leadership roles at Takeda and Pfizer developing and executing real-world data initiatives.
“SHYFT’s QUANTUM platform represents truly disruptive technology that fulfills the substantial value and evidence needs of the life science industry with unprecedented efficiency,” Lempernesse said. “I’m thrilled to be a part of a team driving market-wide transformation.”
“SHYFT spent several years developing ground-breaking software for real-world evidence and delivering value to life science partners,” said Zack King, president of SHYFT and executive vice president, Medidata. “We are incredibly fortunate to add Bruno and Aaron to our expert RWE solutions team to execute some of our customers’ most important work. Their combined experience and leadership will ensure that SHYFT continues to be at the forefront of the digital transformation in healthcare.”
SHYFT Analytics, a Medidata company, is the leading platform for commercial and real-world data analytics with products designed specifically for the pharmaceutical, biotech, and medical device industry. SHYFT’s data analytics platform is the most efficient and scalable way to transform massive amounts of complex healthcare data into on-demand clinical and commercial insight. SHYFT is headquartered in Boston with offices in San Francisco and New York City. Learn more about SHYFT at www.shyftanalytics.com, or follow the company on Twitter @SHYFTAnalytics or LinkedIn.
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.medidata.com